Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines

LY3023414 (samotolisib) is a promising new dual inhibitor of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). Currently, multiple clinical trials are underway to evaluate the efficacy of LY3023414 in patients with various types of cancer. However, the potential mechanisms u...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Biochem Pharmacol
Main Authors: Wu, Chung-Pu, Hung, Cheng-Yu, Lusvarghi, Sabrina, Huang, Yang-Hui, Tseng, Pin-Jung, Hung, Tai-Ho, Yu, Jau-Song, Ambudkar, Suresh. V.
Formato: Artigo
Idioma:Inglês
Publicado: 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7606332/
https://ncbi.nlm.nih.gov/pubmed/32634436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2020.114137
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares